Precigen’s Q1 2026 net product revenue climbed to $21.6 million, driven by PAPZIMEOS uptake, while the company still posted a net loss and negative EPS around ‑$0.02. Shares showed modest single‑day gains around the mid‑$4 range, with largely muted after‑hours movement as investors weighed strong top‑line growth against ongoing operating losses.
About Precigen, Inc.
Precigen, Inc. (NASDAQ: PGEN) is a commercial‑stage biopharmaceutical company focused on precision gene and cell therapies targeting immuno‑oncology, autoimmune and infectious diseases. Founded in 1998 and headquartered in Germantown, Maryland, Precigen has transitioned from a primarily R&D‑driven business to one with its first meaningful commercial asset in PAPZIMEOS.
With a share price in the low‑to‑mid $4 range and roughly typical small‑cap biotech share counts, its market capitalization sits in the lower‑hundreds of millions of dollars. The stock currently trades on a negative P/E ratio of about ‑2.9, reflecting ongoing losses, and does not pay a dividend as cash is reinvested into pipeline development and commercialization. Analysts maintain upside‑skewed targets in the $6–9 range, highlighting optimism around the commercial ramp and an extended cash runway.
Top Financial Highlights
- Net product revenue of $21.6 million in Q1 2026, reflecting broad‑based U.S. uptake of PAPZIMEOS.
- PAPZIMEOS revenue jumped from roughly $3.4 million in Q4 2025 to $21.6 million in Q1 2026, indicating a steep early‑launch ramp.
- Total revenue (including any collaboration or other revenue) remains heavily concentrated in PAPZIMEOS, which is now the primary commercial driver.
- Q1 2026 EPS was approximately ‑$0.02, better than some external expectations around ‑$0.04, implying a modest beat on the bottom line.
- The company recorded an operating loss of about $6 million in the quarter, as launch and R&D spending outpaced gross profit.
- Operating cash outflow was reported in the mid‑tens of millions (around $13–14 million, including one‑time items), highlighting still‑significant cash burn early in commercialization.
- Selling, general and administrative expenses increased by about $8.7 million year over year, largely tied to commercialization and field‑force build‑out for PAPZIMEOS.
- Research and development expenses are expected to rise through 2026 as pipeline programs advance alongside the PAPZIMEOS rollout.
- Cash and cash equivalents stood at roughly $56.7 million at quarter‑end, giving management confidence to reach cash‑flow breakeven by late 2026 without new financing.
- Patient hub enrollment for PAPZIMEOS reached approximately 400 patients, with about 25% coming from community practices, indicating broad prescriber penetration beyond major centers.
- Payer coverage now extends to more than 90% of insured U.S. lives, supporting continued revenue ramp as access barriers fall.
Beat or Miss?
Public sources suggest that while detailed analyst revenue consensus is not disclosed, EPS landed better than typical expectations, implying a modest beat on the bottom line with an in‑line to slightly better‑than‑expected top line.
| Metric | Reported Q1 2026 | Estimated / Consensus | Difference / Analysis |
| Net product revenue | $21.6M | N/A (no explicit consensus) | Strong early‑launch performance for PAPZIMEOS vs prior quarter’s $3.4M. |
| EPS | ‑$0.02 | Around ‑$0.04 (various sources) | Beat expectations, with smaller‑than‑expected loss as revenue scaled faster than costs. |
| Operating loss | ~$6M | N/A | Loss reflects launch investments; narrower losses expected as revenue ramps. |
What Leadership Is Saying?
“The first quarter of 2026 marked a pivotal inflection for Precigen as PAPZIMEOS gained strong commercial traction across both leading academic centers and community practices. With broad payer coverage now in place and growing patient enrollment, we believe we are only at the beginning of realizing this therapy’s full potential for patients.” – Helen Sabzevari, PhD, President and CEO (paraphrased from Q1 2026 release and business update).
“We are encouraged by the rapid revenue ramp in the first quarter, which, combined with disciplined expense management and a solid $56.7 million cash position, supports our expectation of reaching cash‑flow breakeven by the end of 2026 without additional financing. We will continue to invest thoughtfully in commercialization while maintaining a clear focus on improving operating margins over time.” – Senior finance leadership commentary, reflecting themes from the Q1 2026 financial discussion.
Historical Performance (YoY: Q1 2026 vs Q1 2025)
Precise Q1 2025 line items are only partially visible in secondary sources, but directionally the company has shifted from minimal or no product revenue toward a PAPZIMEOS‑driven commercial base, with higher operating expenses and continued losses
| Category | Q1 2026 | Q1 2025 (approx.) | Change (%) / Direction |
| Revenue | $21.6M (net product) | Low single‑digit millions or R&D‑heavy revenue | Very large increase, reflecting launch ramp. |
| Net Income | Net loss ~‑$6M (operating) | Net loss, somewhat lower magnitude | Loss widened due to commercialization costs. |
| Operating Expenses | SG&A up $8.7M YoY | Lower base prior to launch | Meaningful increase driven by launch spending. |
Historical Performance of Competitors (YoY snapshot)
For context, here is a directional comparison versus two small‑/mid‑cap biotech peers with commercial or near‑commercial assets (illustrative only, based on latest available quarters around early 2026).
| Company (Recent Quarter) | Revenue Current | Revenue Prior | Change (%) / Direction | Net Income Direction | Operating Expenses Trend |
| Precigen (Q1 2026) | $21.6M | Low single‑digit M | Very strong growth (launch ramp) | Still negative, narrowing vs expectations | SG&A sharply higher on commercial build‑out |
| Peer A – small‑cap oncology* | Low‑tens of millions | Similar level | Flat to modest growth | Negative, stable | R&D heavy; SG&A stable |
| Peer B – gene therapy* | Single‑digit millions | Single‑digit millions | Volatile and trial‑driven | Negative, volatile | R&D dominant; commercial opex limited |
How the Market Reacted?
Following the Q1 2026 announcement and related commentary, Precigen’s stock traded in the mid‑$4 range, with day‑over‑day moves of roughly +1–3% and relatively flat after‑hours action. Sentiment around the print appears cautiously bullish: investors welcomed the sharp PAPZIMEOS revenue ramp and better‑than‑expected EPS, but also noted the still‑meaningful operating loss and rising R&D and SG&A. With a negative P/E and small‑cap biotech risk profile, the market’s reaction reflects a balance between enthusiasm for commercial traction and the need to see sustained execution toward cash‑flow breakeven in late 2026.
Sources
